CMS/NCI Collaboration Will Use Cancer As Model For Evidence-Based Reimbursement
This article was originally published in The Pink Sheet Daily
Executive Summary
Inter-agency task force is examining how to link reimbursement to the “new paradigm” of drug discovery, NCI Director von Eschenbach says. Collaboration builds on an FDA/NCI agreement aimed at speeding development of cancer drugs.
You may also be interested in...
NCI/FDA Task Force Will Serve As Resource During Approval Process
NCI-funded investigators who reach an impasse in the regulatory process can utilize the "leadership group" of the FDA/NCI Interagency Oncology Task Force. The task force is converting its work into FDA guidance documents.
NCI/FDA Task Force Will Serve As Resource During Approval Process
NCI-funded investigators who reach an impasse in the regulatory process can utilize the "leadership group" of the FDA/NCI Interagency Oncology Task Force. The task force is converting its work into FDA guidance documents.
CMS/NCI Collaboration Will Encompass Post-Approval Studies
Memorandum of understanding will create a mechanism to identify “high-priority clinical questions.” The collaboration also will examine off-label coverage of cancer drugs and reimbursement for new technologies.